|Day Low/High||175.71 / 181.22|
|52 Wk Low/High||123.73 / 182.47|
U.S. markets ended Monday's session in the green as deal news boosted the health care sector following Shire's announcement that it would acquire drugmaker Dyax.
This is what matters in making more money for your portfolio.
Stocks started November on strong footing, extending October's stellar run.
Here are some of the best pharmaceuticals our algorithm says you should consider looking at.
Drug manufacturer Baxalta (BXLT) was the best performing stock in the S&P 500 Tuesday after an unsolicited takeover offer from a competitor. The stock is TheStreet's Move of the Day.
Baxalta (BXLT) shares were on watch after the company rejected an unsolicited offer from Shire (SHPG).
Shire (SHPG) has announced an offer to buy Baxalta (BXLT), a rare disease treatment specialist based in the U.S., for around $30.6 billion in stock.
Where it began. "As I mentioned earlier, the divergences seen since late summer are starting to weigh on stocks: "Underperformance of the Russell Index. "Weakening in the cumulative advance/decline line of the Nasdaq. "Contraction in the number of ...
The futures markets are mixed this morning as news of the Malaysian Airlines plane shot down in the Ukraine and tensions in Gaza dominate investors minds.
Shire's purchase of ViroPharma is a signal of deals and higher prices ahead, says Jason Kolbert, Sr. Research Analyst at the Maxim Group.
These three medical stocks are moving up in heavier-than-normal volume.